Information Provided By:
Fly News Breaks for April 24, 2015
BCR
Apr 24, 2015 | 09:37 EDT
BofA/Merrill upgraded C.R. Bard two notches to Buy from Underperform and increased its price target to $200 following Q1 results. The firm sees upside to Bard's drug eluting balloon franchise following the report and recent survey results, and expects the company to utilize its under leverage balance sheet in 2015.
News For BCR From the Last 2 Days
There are no results for your query BCR